Company intelligence / Profile preview

Storm Construction

Cambridge, Cambridgeshire, United Kingdomstormconst.net ↗

Ownership: Private
Development stage: Other

Overview

STORM Therapeutics has advanced its lead candidate, STC‑15—a first-in-class oral METTL3 inhibitor—into Phase 1 clinical trials for cancer. Early data and IND filings support its potential as the first therapy targeting an RNA modifying enzyme to enter human studies. The broader pipeline includes additional small molecules targeting other RNA modifying enzymes with applications across oncology and other disease areas.

Therapeutic areas: Infectious DiseasesImmunologyNeurologyOncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Leading oncology company for ADAR1-targeting drug discovery [name not disclosed publicly as of latest reports].

Beyond the preview

Go deeper on Storm Construction.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Storm Construction.

Explore the full profile